We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+20.93%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$952M
AUM Growth
+$119M
(+14%)
Cap. Flow
-$4.06M
Cap. Flow
% of AUM
-0.43%
Top 10 Holdings %
Top 10 Hldgs %
45.23%
Holding
168
New
60
Increased
16
Reduced
31
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$23.5M |
| 2 |
PTC Therapeutics
PTCT
|
+$18.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$16.8M |
| 4 |
Travere Therapeutics
TVTX
|
+$16.1M |
| 5 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$15.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$48M |
| 2 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$31.8M |
| 3 |
MannKind Corp
MNKD
|
+$19.8M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$18.2M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.36% |
| 2 | Miscellaneous | 16.85% |
| 3 | Consumer Staples | 1.74% |
| 4 | Technology | 0.04% |
| 5 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viatris
VTRS
$19.1B
| $11.4M | 1.19% |
232,500
-160,000
| -41% | -$7.77M |
|
|
TARO
27
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $10.8M | 1.13% |
97,011
+40,409
| +71% | +$4.4M |
|
|
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
| $10.7M | 1.13% |
+800,000
| New | +$8.57M |
|
|
ECYT
29
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $10.4M | 1.09% |
435,000
-236,300
| -35% | -$3.43M |
|
|
SPNC
30
DELISTED
Spectranetics Corp
SPNC
| $10.1M | 1.06% |
332,554
-13,700
| -4% | -$375K |
|
31
Incyte
INCY
$24.7B
| $9.84M | 1.03% |
183,800
-85,000
| -32% | -$5.28M |
|
|
ISEE
32
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.94M | 0.94% |
250,000
+175,000
| +233% | +$5.9M |
|
|
ITMN
33
DELISTED
INTERMUNE INC
ITMN
| $8.7M | 0.91% |
+260,000
| New | +$5.79M |
|
|
34
CALL
Sarepta Therapeutics
SRPT
$2.19B
| $8.41M | 0.88% |
+350,000
| New | +$8.92M |
|
35
HCA Healthcare
HCA
$91.8B
| $7.88M | 0.83% |
+150,000
| New | +$7.46M |
|
|
CHTP
36
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| $7.18M | 0.76% |
1,301,639
-400,000
| -24% | -$2.01M |
|
|
DSCI
37
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $6.76M | 0.71% |
+532,800
| New | +$6.89M |
|
38
CALL
Cytokinetics
CYTK
$9.64B
| $6.65M | 0.7% |
+700,000
| New | +$6.33M |
|
39
Insmed
INSM
$26.2B
| $6.47M | 0.68% |
+340,000
| New | +$6.46M |
|
|
ADYX
40
DELISTED
Adynxx Inc
ADYX
| $6.47M | 0.68% |
+13,077
| New | +$6.83M |
|
|
TRVN
41
DELISTED
Trevena, Inc.
TRVN
| $6.05M | 0.64% |
+1,232
| New | +$6.04M |
|
|
RLYP
42
DELISTED
RELYPSA INC COM
RLYP
| $5.4M | 0.57% |
181,200
-160,000
| -47% | -$5.78M |
|
43
Sonida Senior Living
SNDA
$1.91B
| $5.26M | 0.55% |
13,500
-417
| -3% | -$151K |
|
44
Arrowhead Research
ARWR
$9.98B
| $5.21M | 0.55% |
+317,300
| New | +$5.57M |
|
|
ENZY
45
DELISTED
Enzymotec Ltd
ENZY
| $4.72M | 0.5% |
+214,219
| New | +$5.68M |
|
|
KERX
46
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $4.69M | 0.49% |
+275,000
| New | +$4.15M |
|
47
Globus Medical
GMED
$10B
| $4.52M | 0.47% |
+170,000
| New | +$4.04M |
|
|
AERI
48
DELISTED
Aerie Pharmaceuticals
AERI
| $4.48M | 0.47% |
211,518
-88,482
| -29% | -$1.79M |
|
|
SHPG
49
DELISTED
Shire pic
SHPG
| $4.46M | 0.47% |
30,000
+20,000
| +200% | +$3.08M |
|
50
Gilead Sciences
GILD
$181B
| $3.54M | 0.37% |
50,000
| – | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2014 Portfolio in Review
As of Q1 2014, Perceptive Advisors held 168 positions worth $952M, up 14% from $833M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Perceptive Advisors's Q1 2014 filing shows 60 new, 16 increased, 31 reduced and 41 closed positions. Its largest new stake was Heron Therapeutics: 1,762,426 shares worth $24.5M. The largest sale was Celgene Corp, an estimated $48M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q1 2014 buy was Heron Therapeutics: 1,762,426 shares worth $24.5M.
- Perceptive Advisors added most to Clovis Oncology, Inc. in Q1 2014, an estimated $10.4M increase.
- Perceptive Advisors's biggest Q1 2014 reduction was Celgene Corp, cutting an estimated $48M.
- Perceptive Advisors fully exited Aegerion Pharmaceuticals in Q1 2014, selling an estimated $31.8M.
- Perceptive Advisors's ten largest holdings make up 45% of its $952M portfolio in Q1 2014.
- Perceptive Advisors opened 60 new positions and closed 41 in Q1 2014.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $952M.
Based on Perceptive Advisors's 13F filing for Q1 2014, filed 15 May 2014.